Neurological & CognitiveIntl. Approved (Russia)S

Semax

ACTH(4-10)-Pro-Gly-Pro

Semax is a synthetic heptapeptide analog of the ACTH 4-7 fragment extended with Pro-Gly-Pro (PGP) to increase CNS stability and activity. Developed in Russia and approved there for stroke treatment, cognitive enhancement, and neuroprotection. Administered intranasally for direct CNS delivery. Robust Russian clinical literature; not FDA-approved in the US. Widely used as a research nootropic.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
5
Research grade
S
Community score
117

Trend index

Trackers
1,802

Overview

About Semax

Semax is a synthetic heptapeptide analog of the ACTH 4-7 fragment extended with Pro-Gly-Pro (PGP) to increase CNS stability and activity. Developed in Russia and approved there for stroke treatment, cognitive enhancement, and neuroprotection. Administered intranasally for direct CNS delivery. Robust Russian clinical literature; not FDA-approved in the US. Widely used as a research nootropic.

Category
Neurological & Cognitive
Regulatory status
Intl. Approved (Russia)
Also known as
ACTH(4-10)-Pro-Gly-Pro
Self-reports
74

Community

What 74 users report

74 community reports

Positive 97% · Neutral 3% · Negative 0%

Most reported benefits

Mood
197
Cognition
196
Energy
1

Most reported side effects

Injection site irritation
5

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
0
100–200
37
200–400
71
400–600
41
600–1000
45
1000–2000
2
2000+
1

How repeat users are trending

Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 46 days · Based on 37 repeat reporters

Research

Cited research (3)

PubMed

Semax, an analog of ACTH(4-7), regulates expression of immune response genes

Dmitrieva et al., 2013

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about Semax?

This page summarizes 74 anonymized self-reports from PeptIQ users who track Semax, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Semax?

3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Semax safe to use?

This wiki does not assess safety or recommend use. Semax is listed as Intl. Approved (Russia). Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Semax?

Research, primarily in animal models, suggests Semax may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Semax?

Semax is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Semax as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Semax?

The safety and effectiveness of Semax have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Semax?

While there are over 200 published studies on Semax, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source